InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
InflaRx (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, will release its fourth quarter and full year 2024 financial results on March 20, 2025, without a conference call.
The company will participate in two upcoming investor conferences: the Leerink Global Healthcare Conference (March 9-12 in Miami Beach) featuring a fireside chat on March 10 at 10:40 AM ET, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, with a virtual fireside chat at 8:30 AM ET. Both events will include one-on-one investor meetings.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate is vilobelimab, an intravenous anti-C5a monoclonal antibody, and they're also developing INF904, an oral C5a receptor inhibitor.
InflaRx (Nasdaq: IFRX), una compagnia biofarmaceutica che sviluppa terapie anti-infiammatorie mirate al sistema del complemento, pubblicherà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 il 20 marzo 2025, senza una conferenza telefonica.
L'azienda parteciperà a due prossimi conferenze per investitori: la Leerink Global Healthcare Conference (dal 9 al 12 marzo a Miami Beach) con un colloquio informale il 10 marzo alle 10:40 ET, e la H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference il 27 marzo, con un colloquio virtuale alle 8:30 ET. Entrambi gli eventi includeranno incontri individuali con gli investitori.
InflaRx si specializza nello sviluppo di inibitori del fattore di attivazione del complemento C5a e del suo recettore C5aR. Il loro principale candidato prodotto è vilobelimab, un anticorpo monoclonale anti-C5a per somministrazione endovenosa, e stanno anche sviluppando INF904, un inibitore orale del recettore C5a.
InflaRx (Nasdaq: IFRX), una compañía biofarmacéutica que desarrolla terapias antiinflamatorias dirigidas al sistema del complemento, publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el 20 de marzo de 2025, sin una llamada de conferencia.
La empresa participará en dos próximas conferencias para inversores: la Leerink Global Healthcare Conference (del 9 al 12 de marzo en Miami Beach) con una charla informal el 10 de marzo a las 10:40 AM ET, y la H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference el 27 de marzo, con una charla virtual a las 8:30 AM ET. Ambos eventos incluirán reuniones individuales con inversores.
InflaRx se especializa en el desarrollo de inhibidores del factor de activación del complemento C5a y su receptor C5aR. Su principal candidato a producto es vilobelimab, un anticuerpo monoclonal anti-C5a intravenoso, y también están desarrollando INF904, un inhibidor oral del receptor C5a.
InflaRx (Nasdaq: IFRX)는 보Complement 시스템을 목표로 하는 항염증 치료제를 개발하는 생명공학 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 3월 20일에 발표할 예정이며, 컨퍼런스 콜은 진행하지 않습니다.
회사는 두 개의 다가오는 투자자 컨퍼런스에 참여할 것입니다: Leerink Global Healthcare Conference (3월 9-12일, 마이애미 비치)에서 3월 10일 오전 10:40 ET에 진행되는 화상 대화와, H.C. Wainwright 제3회 자가면역 및 염증 질환 가상 컨퍼런스가 3월 27일에 열리며, 오전 8:30 ET에 화상 대화가 진행됩니다. 두 행사 모두 개별 투자자 회의가 포함됩니다.
InflaRx는 보Complement 활성화 인자 C5a와 그 수용체 C5aR의 억제제를 개발하는 데 전문화되어 있습니다. 그들의 주요 제품 후보는 vilobelimab로, 정맥 주사용 항-C5a 단클론 항체이며, INF904라는 경구용 C5a 수용체 억제제도 개발하고 있습니다.
InflaRx (Nasdaq: IFRX), une société biopharmaceutique développant des thérapeutiques anti-inflammatoires ciblant le système du complément, publiera ses résultats financiers du quatrième trimestre et de l'année 2024 le 20 mars 2025, sans conférence téléphonique.
La société participera à deux prochaines conférences pour investisseurs : la Leerink Global Healthcare Conference (du 9 au 12 mars à Miami Beach) avec un entretien informel le 10 mars à 10h40 ET, et la H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference le 27 mars, avec un entretien virtuel à 8h30 ET. Les deux événements incluront des réunions individuelles avec des investisseurs.
InflaRx se spécialise dans le développement d'inhibiteurs du facteur d'activation du complément C5a et de son récepteur C5aR. Leur principal candidat produit est vilobelimab, un anticorps monoclonal anti-C5a administré par voie intraveineuse, et ils développent également INF904, un inhibiteur oral du récepteur C5a.
InflaRx (Nasdaq: IFRX), ein biopharmazeutisches Unternehmen, das entzündungshemmende Therapeutika entwickelt, die auf das Komplementsystem abzielen, wird seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am 20. März 2025 veröffentlichen, ohne eine Telefonkonferenz.
Das Unternehmen wird an zwei bevorstehenden Investorenkonferenzen teilnehmen: der Leerink Global Healthcare Conference (9.-12. März in Miami Beach), die am 10. März um 10:40 Uhr ET ein informelles Gespräch bietet, und der H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference am 27. März, mit einem virtuellen Gespräch um 8:30 Uhr ET. Beide Veranstaltungen beinhalten Einzelgespräche mit Investoren.
InflaRx hat sich auf die Entwicklung von Inhibitoren des Komplementaktivierungsfaktors C5a und seines Rezeptors C5aR spezialisiert. Ihr Hauptproduktkandidat ist vilobelimab, ein intravenöses anti-C5a monoklonales Antikörper, und sie entwickeln auch INF904, einen oralen C5a-Rezeptor-Inhibitor.
- None.
- None.
JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned.
InflaRx also announced that it will participate in two investor conferences. Details are as follows:
Leerink Global Healthcare Conference
March 9 - 12, 2025 in Miami Beach, FL
InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to register for the fireside chat live stream and its replay is available here.
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 27, 2025
InflaRx will conduct a virtual fireside chat on March 27 at 8:30 AM ET and will participate in one-on-one-investor meetings. A link to register for the fireside chat live stream and its replay is available here.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When will InflaRx (IFRX) release its full year 2024 financial results?
Which investor conferences will InflaRx (IFRX) attend in March 2025?
What is InflaRx's (IFRX) lead product candidate?
What therapeutic area does InflaRx (IFRX) focus on?
What products are in InflaRx's (IFRX) development pipeline?
